纳武单抗联合雷莫西尤单抗治疗不可切除的晚期或复发性胃癌患者的临床疗效与安全性
[Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer].
作者信息
Murakami Kohei, Takeno Atsushi, Masuzawa Toru, Imada Ayako, Takase Koki, Toya Keisuke, Yukawa Yoshiro, Kawai Kenji, Sakamoto Takuya, Katsura Yoshiteru, Ohmura Yoshiaki, Kagawa Yoshinori, Hata Taishi, Takeda Yutaka, Murata Kohei
机构信息
Dept. of Surgery, Kansai Rosai Hospital.
出版信息
Gan To Kagaku Ryoho. 2020 Mar;47(3):493-495.
We retrospectively evaluated the efficacy and feasibility of the combination of nab-paclitaxel plus ramucirumab(nab-PTX plus RAM)for the treatment of unresectable or recurrent gastric cancer. Sixteen patients received nab-PTX plus RAM. The overall response rate was 37.5%, and disease control rate was 87.5%. The median progression-free survival was 5.0 months. Grade 3 or higher adverse events(neutropenia: 62.5%, leukopenia: 18.8%, decrease appetite: 6.3%, hypertension: 6.3%, and proteinuria: 12.5%)were observed. Although dose reduction of nab-PTX was required in 93.8% of the patients, no adverse event that led to the discontinuation of treatment. Nab-PTX plus RAM combination therapy showed promising efficacy and manageable toxicities and could be a viable treatment option for patients with advanced gastric cancer.
我们回顾性评估了纳武单抗联合雷莫西尤单抗（纳武单抗联合雷莫西尤单抗）治疗不可切除或复发性胃癌的疗效和可行性。16例患者接受了纳武单抗联合雷莫西尤单抗治疗。总缓解率为37.5%，疾病控制率为87.5%。中位无进展生存期为5.0个月。观察到3级或更高等级的不良事件（中性粒细胞减少：62.5%，白细胞减少：18.8%，食欲下降：6.3%，高血压：6.3%，蛋白尿：12.5%）。尽管93.8%的患者需要减少纳武单抗剂量，但没有导致治疗中断的不良事件。纳武单抗联合雷莫西尤单抗联合治疗显示出有前景的疗效和可管理的毒性，可能是晚期胃癌患者的一种可行治疗选择。
Zotero 插件